THE FUTURE OF ADVANCED THERAPIES

 

3,300+

Attendees

300+

Speakers

200+

Exhibitors

75+

Biotech Start-Ups

2

Days

 

About Advanced Therapies Congress

 

The Advanced Therapies Congress is Europe's largest commercial cell and gene therapy conference and exhibition. The event is for the leaders of pioneering ATMP companies and their most senior executives in charge of the latest tech and strategies that are driving the industry forward.
 
The conferences brings together a community of 3,300 global executives at ExCeL London, to be inspired by 300 speakers and 75 start-ups over 2 incredible days. The Advanced Therapies Congress features speakers from across the entire value chain of cell and gene therapy development; forward-thinking pharma, biotech and start- up companies, researchers, clinicians, academics, HTAs, payers and regulators.

What is the Advanced Therapies Congress?

 

Conference

The Advanced Therapies Congress features speakers from across the entire value chain of cell and gene therapy development with 8 tracks of content over 2 days.

Exhibition

50 leading solution providers to meet your needs across all stages of cell and gene therapy development
 

DOWNLOAD PROSPECTUS

Networking

Connect with thousands of cell and gene therapy experts in 12+ hours of built-in 1-2-1 networking
 
 

GET YOUR TICKET 

Our Speakers

 

Eric David
Chief Executive Officer of Gene Therapy
BridgeBio Gene Therapy
Eric David speaking at Advanced Therapies Congress
Pamela Tranter
Head, Translational Research Group
UCL Translational Research Office
Pamela Tranter speaking at Advanced Therapies Congress
Bobby Gaspar
CEO
Orchard Therapeutics
Bobby Gaspar speaking at Advanced Therapies Congress
Tara Sadeghi
Chief Operating Officer
Cellenkos Inc.
Tara Sadeghi speaking at Advanced Therapies Congress
Chris Williams
Chief Business Officer
Autolus
Chris Williams speaking at Advanced Therapies Congress
Christopher Baldwin
Vice President, Manufacturing and Supply
Resolution Therapeutics
Christopher Baldwin speaking at Advanced Therapies Congress
Jaap Boelens
Chief Stem Cell Transplantation & Cellular Therapies Pediatrics
Memorial Sloan Kettering Cancer Center
Jaap Boelens speaking at Advanced Therapies Congress
Katja Berg
Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU
AstraZeneca
Katja Berg speaking at Advanced Therapies Congress
Owen Bain
Director/Qualified Person, Centre for Cell Gene and Tissue Therapeutics
Royal Free London NHS Foundation Trust
Owen Bain speaking at Advanced Therapies Congress
Henriette Burghoorn
Associate Director, Market Access
Gilead Sciences
Henriette Burghoorn speaking at Advanced Therapies Congress
Maike de la Roche
Senior Group Leader
CRUK Cambridge Institute
Maike de la Roche speaking at Advanced Therapies Congress
Nick France
Vice President, Head: Genomic Medicine Development Unit
Alexion, AstraZeneca Rare Disease
Nick France speaking at Advanced Therapies Congress

 

Covering the entire pipeline of ATMPs

The Advanced Therapies Congress brings together speakers from across the entire value chain of cell and gene therapy development; forward-thinking pharma, biotech and startup companies, researchers, clinicians, academics, HTAs, payers, regulators.

Get your ticket now

Content Themes

 
Evidence, Pricing & Access
Ensuring clinical success - Tackling large scale regulatory challenge - Finding the right framework for reimbursement and market access - Cross-border healthcare - Outcome based agreements
Gene Modified Cell Therapy
Autologous vs allogeneic - Tackling solid tumours - Combination therapy - CAR-T, NK, Gamma-Delta cells - Patient stratification and precision medicine approaches
Cell Therapy
Stem cells - Regenerative Medicine - MSCs vs iPSCs - Cord blood advancements
Gene Therapy
Next generation of gene therapy - Moving from rare to more common diseases - Tackling immunogenicity - Rare diseases & orphan drugs - Novel gene delivery systems
Cell Therapy Manufacturing
Automation & closed systems - Scaling up to commercial level - Keeping costs low - In house vs outsourcing
Viral Vector Manufacturing
Continuous manufacturing - Scaling up for commercial production - In house vs outsourcing
Clinical Trials & Development
Ensuring clinical success - Clinical and nursing perspectives - Moving from clinical to commercial
Gene Editing
Latest cutting edge technology - Latest academic research - Safety & ethics
Immunotherapy
Immunotherapy for solid tumours - AI in oncology - Precision medicine
Supply Chain & Logistics
Logistics, transportation, distribution & cold chain - Moving from clinical to commercial - Patient experience - Supply chain - Point of care delivery
Regulation
Tackling large scale regulatory challenges - Patient informed policy decisions
Innovation Showcase
Latest in academic research - Latest cutting-edge technologies success - Tackling large scale regulatory challenges - Finding the right framework for reimbursement and market access - Cross-border healthcare - Outcome based agreements
Start-ups
Company presentations from exciting new start-ups - Investor perspectives
patient delivery
Challenges in clinical adoption, patient pathways and improving accessibility, Initial and ongoing care


"Great people and content; lots of opportunities to dialogue with experts on our sector"

– President & CEO, NKILT Therapeutics

 
"Excellent networking activities with top level actors in the field of advanced therapies"

– Professor, University of Pisa
 
"Great mix of suppliers, manufacturers, Sponsors, exhibitors and presentations"

– Vice President of Operations, Adaptimmune

 

Join us in London | 17 - 18 March 2026

 

 

 

GET YOUR TICKET NOW


Get Involved with Advanced Therapies Congress

 

To sponsor or exhibit

Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

To speak

Chris Shanks
Chris.Shanks@terrapinn.com
+44 207 092 1150